Early Diagnosis Of Cancer Saves Human Lives
Pioneering breakthroughs in molecular diagnostics of cancer to save human lives worldwide
Pioneering breakthroughs in molecular diagnostics of cancer to save human lives worldwide
We are dedicated to providing a non-invasive method for an accurate early diagnosis of human cancer affordable to everyone everywhere.
The importance of Early Cancer Diagnosis is underscored by the World Health Organisation as below.
"Early diagnosis of cancer focuses on detecting symptomatic patients as early as possible so they have the best chance for successful treatment. When cancer care is delayed or inaccessible there is a lower chance of survival, greater problems associated with treatment and higher costs of care. Early diagnosis improves cancer outcomes by providing care at the earliest possible stage and is therefore an important public health strategy in all settings." Light-Hope Diagnostics, Inc. is at the forefront of developing non-invasive tests for early cancer diagnosis by detecting cancer-specific non-coding RNAs in liquid biopsy. RNA is a robust biomarker for early detection of human cancer with high specificity and sensitivity.
We are currently performing the analytical/clinical validation of our first PCR-based IVD product for early diagnosis of breast cancer. Our tests rely on RNA biomarkers, which are a group of genetic markers present in liquid biopsy (blood, urine, and saliva). The RNA-based early detection of cancer using liquid biopsy is a promising technology that has potential to revolutionize cancer diagnosis and screening, and save countless human lives.
Our forthcoming IVD products for early diagnosis of the following cancer are in the research and development phase.
Our long-term goal is to develop a Multi-cancer Early Detection (MCED) Test which can simultaneously detect at least five major forms of human cancer, namely, breast, ovarian, lung, pancreatic, and prostate.
Cold chain management is essential for maintaining the stability of PCR-based IVD products. Utilizing our 20+ years of experience in enzymology, DNA/RNA biochemistry, and protein science, we have developed a proprietary freeze-drying (lyophilization) method for long-term stabilization of our IVD products at a higher ambient temperature (60-120 degree Fahrenheit). This feature virtually eliminates the cold chain requirement for our products (even in tropical countries, e.g., India, Africa) and markedly reduces their cost--and thereby makes them affordable and accessible worldwide.
We are actively looking for investors, collaborators, and advisors both in the USA as well as in India to partner with us. So, please feel free to contact us.
48 Rio Grande Street, Salt Lake City, Utah 84101, United States
Mon | By Appointment | |
Tue | By Appointment | |
Wed | By Appointment | |
Thu | By Appointment | |
Fri | By Appointment | |
Sat | Closed | |
Sun | Closed |
We look forward to potential collaborations with people and organizations interested in working with us.
We use cookies to analyze website traffic and optimize your website experience. By accepting our use of cookies, your data will be aggregated with all other user data.